Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events.

Ptaszynska A, Johnsson KM, Parikh SJ, de Bruin TW, Apanovitch AM, List JF.

Drug Saf. 2014 Oct;37(10):815-29. doi: 10.1007/s40264-014-0213-4.

PMID:
25096959
[PubMed - in process]
2.

Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time.

Parikh S, Wilding J, Jabbour S, Hardy E.

Int J Clin Pract. 2014 Nov 28. doi: 10.1111/ijcp.12531. [Epub ahead of print]

PMID:
25438821
[PubMed - as supplied by publisher]
3.

Dapagliflozin: a review of its use in type 2 diabetes mellitus.

Plosker GL.

Drugs. 2012 Dec 3;72(17):2289-312. doi: 10.2165/11209910-000000000-00000. Review.

PMID:
23170914
[PubMed - indexed for MEDLINE]
4.

Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin.

Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF.

J Diabetes Complications. 2013 Sep-Oct;27(5):479-84. doi: 10.1016/j.jdiacomp.2013.04.012. Epub 2013 Jun 24.

PMID:
23806570
[PubMed - indexed for MEDLINE]
5.

Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.

Ji L, Ma J, Li H, Mansfield TA, T'joen CL, Iqbal N, Ptaszynska A, List JF.

Clin Ther. 2014 Jan 1;36(1):84-100.e9. doi: 10.1016/j.clinthera.2013.11.002. Epub 2013 Dec 28.

PMID:
24378206
[PubMed - indexed for MEDLINE]
Free Article
6.

Urinary tract infections in patients with diabetes treated with dapagliflozin.

Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF.

J Diabetes Complications. 2013 Sep-Oct;27(5):473-8. doi: 10.1016/j.jdiacomp.2013.05.004. Epub 2013 Jul 10.

PMID:
23849632
[PubMed - indexed for MEDLINE]
7.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
[PubMed - indexed for MEDLINE]
8.

Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.

Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S; Dapagliflozin 006 Study Group.

Diabetes Obes Metab. 2014 Feb;16(2):124-36. doi: 10.1111/dom.12187. Epub 2013 Aug 29.

PMID:
23911013
[PubMed - in process]
9.

[Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin].

Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, Parikh S; Studiengruppe Dapagliflozin 006.

Dtsch Med Wochenschr. 2013 Apr;138 Suppl 1:S27-38. doi: 10.1055/s-0032-1305284. Epub 2013 Mar 25. German.

PMID:
23529568
[PubMed - indexed for MEDLINE]
10.

[Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin].

Nauck M, del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze M, Parikh SJ.

Dtsch Med Wochenschr. 2013 Apr;138 Suppl 1:S6-15. doi: 10.1055/s-0032-1305283. Epub 2013 Mar 25. German.

PMID:
23529570
[PubMed - indexed for MEDLINE]
11.

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.

Bolinder J, Ljunggren Ö, Kullberg J, Johansson L, Wilding J, Langkilde AM, Sugg J, Parikh S.

J Clin Endocrinol Metab. 2012 Mar;97(3):1020-31. doi: 10.1210/jc.2011-2260. Epub 2012 Jan 11.

PMID:
22238392
[PubMed - indexed for MEDLINE]
12.

Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial.

Kaku K, Inoue S, Matsuoka O, Kiyosue A, Azuma H, Hayashi N, Tokudome T, Langkilde AM, Parikh S.

Diabetes Obes Metab. 2013 May;15(5):432-40. doi: 10.1111/dom.12047. Epub 2013 Jan 25.

PMID:
23194084
[PubMed - indexed for MEDLINE]
13.

Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.

Usiskin K, Kline I, Fung A, Mayer C, Meininger G.

Postgrad Med. 2014 May;126(3):16-34. doi: 10.3810/pgm.2014.05.2753.

PMID:
24918789
[PubMed - indexed for MEDLINE]
14.

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.

Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S.

Diabetes Obes Metab. 2011 Oct;13(10):928-38. doi: 10.1111/j.1463-1326.2011.01434.x.

PMID:
21672123
[PubMed - indexed for MEDLINE]
15.

[Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes].

Albarrán OG, Ampudia-Blasco FJ.

Med Clin (Barc). 2013 Sep;141 Suppl 2:36-43. doi: 10.1016/S0025-7753(13)70062-9. Review. Spanish.

PMID:
24444523
[PubMed - indexed for MEDLINE]
16.

Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.

Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, Parikh S; Dapagliflozin 006 Study Group.

Ann Intern Med. 2012 Mar 20;156(6):405-15. doi: 10.7326/0003-4819-156-6-201203200-00003.

PMID:
22431673
[PubMed - indexed for MEDLINE]
17.

Dapagliflozin: a review of its use in patients with type 2 diabetes.

Plosker GL.

Drugs. 2014 Dec;74(18):2191-209. doi: 10.1007/s40265-014-0324-3.

PMID:
25389049
[PubMed - in process]
18.

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.

Bailey CJ, Gross JL, Pieters A, Bastien A, List JF.

Lancet. 2010 Jun 26;375(9733):2223-33. doi: 10.1016/S0140-6736(10)60407-2.

PMID:
20609968
[PubMed - indexed for MEDLINE]
19.

[Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride].

Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S.

Dtsch Med Wochenschr. 2013 Apr;138 Suppl 1:S16-26. doi: 10.1055/s-0032-1305277. Epub 2013 Mar 25. German.

PMID:
23529567
[PubMed - indexed for MEDLINE]
20.

Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise.

Kaku K, Kiyosue A, Inoue S, Ueda N, Tokudome T, Yang J, Langkilde AM.

Diabetes Obes Metab. 2014 Nov;16(11):1102-10. doi: 10.1111/dom.12325. Epub 2014 Jul 8.

PMID:
24909293
[PubMed - in process]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk